Abstrak
Latar Belakang
Ada ketidakpastian tentang kontribusi bahwa intervensi dukungan sosial (SSI) dapat memiliki dalam memitigasi pribadi, sosial
dan biaya ekonomi tuberkulosis pengobatan (TB) pada pasien, dan hasil pengobatan membaik.
Tujuan
Untuk mengidentifikasi psiko-emosional (PE) dan sosial ekonomi (SE) intervensi yang diberikan kepada pasien TB dan untuk
menilai efek dari intervensi ini pada kepatuhan pengobatan dan hasil pengobatan.
Strategi pencarian
Kami mencari PubMed dan Embase dari 1 Januari 1990-15 Maret 2015 dan abstrak Konferensi Dunia Union tentang Kesehatan
Paru 2010-2014 untuk studi melaporkan pengobatan kepatuhan TB dan hasil pengobatan berikut SSI.
Kriteria seleksi
Studi mengukur efek dari PE atau SE intervensi terhadap kepatuhan pengobatan TB, hasil pengobatan, dan / atau beban
keuangan.
Latar belakang
Pada 2013, 9 juta orang mengembangkan TB dan 1,5 juta meninggal karena penyakit ini [1,2]. TB adalah penyebab
kematian paling umum pada orang dengan HIV [1]. Durasi pengobatan untuk TB panjang, minimal 6 bulan untuk
TB yang rentan terhadap obat dan 18-24 bulan untuk multidrug-resistant tuberculosis (MDR-TB) yang tidak
menanggapi picin dua obat anti-TB yang paling efektif isoniazid dan rifam- . Perlakuan lama, reaksi obat yang
merugikan selama pengobatan, stigma dan beban bagi keuangan TB berkontribusi non-kepatuhan terhadap
pengobatan dan hasil pengobatan tidak berhasil [3- 8]. Selain itu, memastikan kepatuhan pasien terhadap
pengobatan melalui fasilitas berbasis langsung diamati terapi (DOT) bersaing dengan prioritas kerja terkait pasien,
menambah resmi beban dalam hal keuangan yang berasal dari out-of-saku dan biaya tidak langsung yang
berhubungan dengan perawatan [7,9 ], meskipun obat anti-TB yang disediakan secara gratis di sebagian besar
negara [1,10]. Ment improve- cepat gejala TB pada awal pengobatan juga memberikan kontribusi untuk pengobatan
menghentikan pasien pra matang (yaitu mangkir-up) sebagai kepentingan bersaing mengambil prioritas [9,11].
Miskin kepatuhan terhadap pengobatan dan kerugian untuk menindaklanjuti peningkatan morbiditas, mortalitas, dan
risiko pengembangan resistensi obat, dan dapat menyebabkan penularan berkepanjangan TB [12-17].
Kepatuhan terhadap pengobatan tuberkulosis meningkatkan kesempatan untuk sembuh dan mengurangi akuisisi
resistensi obat dan transmisi berkelanjutan TB. Penggunaan DOT melalui pendekatan berpusat pada pasien, yang
sering membutuhkan enabler, dianjurkan untuk mendorong kepatuhan terhadap TB memperlakukan ment [18,19].
Dalam beberapa pengaturan dan keadaan, insentif sendiri atau di samping enabler digunakan untuk memotivasi
pasien untuk mematuhi dan menyelesaikan kursus penuh pengobatan [9,16,20- 22]. Dukungan sosial melalui
berbagai pendidikan, emosional, dan / atau bahan (dalam bentuk atau keburukan ser-) intervensi yang disediakan
oleh banyak program TB untuk menghapus atau meringankan hambatan untuk kepatuhan pengobatan [9,20,23-25],
termasuk keuangan beban yang terkait dengan penyakit TB dan pengobatannya. Terlepas dari kenyataan bahwa
berbagai jenis intervensi dukungan sosial (SSI) dilaksanakan, negara masih berjuang untuk mengembangkan sistem
yang mampu memberikan SSI dengan cara yang efisien, efektif dan berkelanjutan [26]. Pedoman WHO
untukprogram
PLoS ONE| DOI: 10.1371 / journal.pone.0154095 April 28, 2016 2/27
Pengaruh Dukungan Pasien padapengobatan TB Hasil
manajemenTB yang resistan terhadap obat dan Akhir baru Strategi TB merekomendasikan penggunaan SSI pada
pasien TB, meskipun WHO belum sistematis menilai bukti untuk mendukung rekomendasi tersebut [2,19,27]. Oleh
karena itu, tinjauan sistematis literatur yang relevan tentang efek SSI pada kepatuhan pengobatan TB, hasil
pengobatan, dan beban keuangan akan informatif bagi pembuatan kebijakan nasional dan global.
Tujuan utama dari tinjauan sistematis ini adalah untuk mengidentifikasi SSI diberikan kepada pasien TB dan
MDR-TB dan menilai bukti efek mereka pada kepatuhan pengobatan, hasil pengobatan dan beban keuangan yang
terkait dengan penyakit TB. Tujuan kedua adalah untuk menggambarkan sumber dana untuk dan kepemilikan
organisasi lokal di intervensi diidentifikasi.
Metode
Ulasan ini diikuti metode standar seperti yang didefinisikan oleh Cochrane Buku Pegangan untuk Sistematik Ulasan
Intervensi dan Produk Pelaporan Preferred untuk sistematis Ulasan dan Analisis Meta (PRISMA) pedoman [28,29].
PRISMA daftar terlampir dalam informasi pendukung (S1 PRISMA Checklist).
Pencarian literatur
Dalam ulasan ini kami mencari dua kategori utama SSI, yaitu dukungan PE dan dukungan SE. Dukungan PE
meliputi dukungan emosional melalui intervensi psikologis (misalnya konseling oleh petugas kesehatan) dan
dukungan persahabatan melalui penyediaan bantuan bagi pasien untuk berpartisipasi dalam jaringan sosial (misalnya
konseling sebaya untuk pasien dan jaringan dukungan mereka) [19]. Kami tidak menganggap intervensi yang
bertujuan hanya untuk memberikan informasi yang ditingkatkan atau kation edu untuk pasien TB, mengingat
tinjauan sistematis baru-baru ini menunjukkan kurangnya bukti yang berkaitan dengan pengobatan TB [17]. Selain
itu, sistem pengingat tidak dianggap dukungan sosial intervensi tions [30]. Dukungan SE memerlukan jasa
pengiriman, barang-barang material dan / atau bantuan keuangan [19,31,32]. Bantuan keuangan dikategorikan
menurut Richter et al. [7] sebagai”fers langsung trans- uang, seperti uang tunai dibayarkan sebagai bagian dari
sistem jaminan sosial atau insentif program penggantian biaya transportasi, tunjangan pengobatan, dan sejenisnya
yang dibayarkan langsung ke individu yang terkena”. Bantuan tidak langsung didefinisikan sebagai: “transfer tidak
langsung melalui, misalnya, paket makanan atau voucher, voucher perjalanan, dan pembayaran asuransi kesehatan
untuk individu, rumah-memegang atau keluarga”. Beberapa bentuk bantuan tidak langsung juga dapat dikonversi
menjadi uang tunai. Kami termasuk pembebasan pajak di bawah bantuan tidak langsung. Bantuan perusahaan
didefinisikan sebagai”program pelatihan atau kredit mikro yang bertujuan untuk membantu individu atau keluarga
untuk menghasilkan pendapatan” [7]. Kami mencari untuk studi menilai efek dari tions intervensi sosial-ekonomi
dan / atau psiko-emosional pada kepatuhan pengobatan dan / atau hasil pengobatan dan / atau beban keuangan.
Populasi penelitian terdiri dari pasien memulai pengobatan anti-TB, termasuk pengobatan untuk MDR-TB.
Ukuran hasil
kepatuhan pengobatan, hasil pengobatan dan beban keuangan dianggap sebagai ukuran hasil mary pri-. Kepatuhan
dihitung sebagai persentase dari dosis yang ditentukan actu- sekutu diambil. Hasil pengobatan didefinisikan menurut
definisi WHO, di mana penyembuhan dan pengobatan selesai didefinisikan sebagai hasil pengobatan yang berhasil
[1]. Hasil pengobatan tidak berhasil untuk pengobatan TB aktif termasuk kematian, kegagalan pengobatan dan
kehilangan untuk menindaklanjuti (pra viously bernama default). Pasien dengan Transfer-out atau hasil pengobatan
yang hilang dikeluarkan dari analisis. Sebagai waktu mangkir-up per individu tidak tersedia untuk studi melaporkan
hasil pengobatan tetapi tidak kepatuhan pengobatan, untuk studi ini mangkir-up tidak termasuk dalam perhitungan
kepatuhan pengobatan. Beban keuangan adalah
PLoS ONE | DOI: 10.1371 / journal.pone.0154095 April 28, 2016 3/27
Pengaruh Dukungan Pasien pada pengobatan TB Hasil
dilaporkan sesuai dengan definisi yang digunakan dalam studi individu. Kami juga diekstrak tion INFORMATION
tentang bagaimana SSI dibiayai dan terorganisir.
Strategi pencarian
Kami sistematis mencari PubMed dan Embase untuk artikel primer dan ulasan melaporkan SSI dan pengobatan TB
untuk subyek manusia, yang diterbitkan mulai 01 Januari 1990-15 Maret 2015, dengan alasan bahwa informasi lama
yang relevan akan muncul dari tinjauan sebelumnya dan daftar referensi. Kami meninjau daftar referensi dari artikel
diidentifikasi, editorial dan ulasan. Selain itu, kami tangan menggeledah 2010-2014 buku abstrak Konferensi Dunia
Union Kesehatan Paru untuk mengidentifikasi studi terbaru yang tidak dipublikasikan dalam literatur belum. Basis
data- digeledah menggunakan teks strategi pencarian penuh seperti yang dijelaskan di S1 lampiran Web. Kami con-
penulis tacted ketika kami tidak mampu mengekstrak informasi yang diperlukan dari publikasi diidentifikasi pada
SSI disediakan dan dampaknya.
Kriteria kelayakan
kelayakan studi didasarkan pada kriteria inklusi yang telah ditentukan. Studi asli termasuk deskripsi SSI harus
berada di tempat, serta evaluasi dari asosiasi SSI pada kepatuhan pengobatan, hasil pengobatan dan / atau beban
keuangan. Ini dievaluasi baik dengan cara perbandingan antara hasil dari suatu kelompok intervensi dan kelompok
menerima dukungan dard-standar (yang bisa tidak ada atau paket yang lebih terbatas), atau dengan cara
perbandingan terjadinya intervensi pada mereka dengan positif dan hasil negatif (studi kasus-kontrol). Strategi
pencarian dibatasi untuk bahasa tertentu termasuk publikasi di Belanda, Inggris, Perancis, Jerman, Portugis, Rusia
dan Spanyol. Tidak ada batasan usia diterapkan. Kami memilih untuk tidak mengecualikan studi yang tidak
memberikan DOT kepada pasien mereka karena tidak ada bukti kuat bahwa DOT dalam arti yang ketat (yaitu
pengamatan langsung menelan obat) tanpa penyedia DOT mendukung pasien melalui pendidikan dan penyuluhan
meningkatkan hasil pengobatan di bawah program kondisi [22,33].
Hasil
Secara total, kami mengidentifikasi 2443 artikel. Setelah penghapusan 694 duplikat, dua pengulas disaring judul dan
abstrak dari 1752 kutipan. Dua puluh lima artikel yang memenuhi syarat untuk dimasukkan dalam deskripsi studi
termasuk (Gambar 1).
Discussion
This review found that PE and SE support did improve treatment outcomes across a variety of settings and patient
populations, with a tendency towards better outcomes with PE interven- tions or a combined approach. However, the
quality of evidence was classified as “very low” under the GRADE approach. Food supplementation and
counselling were commonly included in the package of support. PE, SE and combined interventions improved
treatment outcomes; only for interventions including SE support exclusively there was no significant improvement
in treatment success. Overall, support interventions were associated with significantly higher treatment success
(overall RR 1.08; CI 1.03–1.13) and reductions in unsuccessful treatment outcomes (overall RR 0.53; CI 0.41–0.70).
Hardly any studies assessed the effect of interven- tions on treatment adherence. However, improved treatment
adherence is an intermediate goal with the final aim to improve treatment outcomes, which was shown to improve.
PLoS ONE | DOI:10.1371/journal.pone.0154095 April 28, 2016 21 / 27
Effects of Patient Support on Tuberculosis Treatment Outcomes
A recent systematic review concluded that the economic burden for patients is considered to be high, loss of
income is an important indirect cost factor for TB patients, and transport and nutritional supplementation were
important direct cost components [8]. A study in Peru evaluated the expenses for MDR-TB patients that received
free treatment and found that hav- ing MDR-TB was associated with high costs, which was associated with adverse
outcomes (population attributable fraction 18–20%) [76]. In line with our review, these two studies sug- gest that
economic support is of great importance for improving treatment outcomes. Some of the findings of this review
however differ from those from other SSI-related reviews. A recent review [77] on RCTs assessing the effect of
material incentives on TB treatment adherence and completion of TB treatment identified two trials, both included
in our review as well [47,60], and neither demonstrated a clear benefit. However, in one trial the incentive was not
well received by the patients and in the other trial fidelity to the intervention was low. A review of Sinclair et al. did
not find any evidence that food supplementation had a beneficial impact on treatment outcomes [78]. This may be
explained by their focus on micronutrient supplementa- tion alone as reflected in their search strategy. In a
systematic review about strategies to reduce loss to follow-up in drug-resistant patients, a comprehensive package of
interventions (eg financial support and food supplementation) was associated with reduced loss to follow-up [79].
Our review included studies focusing on all TB patients, not only those with MDR-TB [79]. As mentioned in the
methods section, we did not consider interventions aimed only at providing improved information or education to
TB patients, given the recent systematic review showing a lack of its evidence related to TB treatment [17]. Some of
the intervention packages included in our review included an information or education component, but it was not
possible to delineate the effects of this specific component in our review. We also did not include interventions
focusing only on reminder systems, as these are not considered PE or SE support. However, reminder systems can
be integrated into SSI programs to enhance its effects since pre-appointment reminder phone calls and letters or
home visits did have a small but potentially relevant effect on treatment completion [30].
There were some limitations to our review. Only a limited number of studies were avail- able on the effect of
PE/SE support interventions on TB treatment outcomes and very lim- ited evidence on treatment adherence and
financial burden. Within the identified studies, we were not able to stratify results by the type of organization and
quality of health service delivery due to insufficient information, although it is known that organization and quality
of health service delivery influence treatment adherence [9]. Some NRSs only provided sup- port to subgroups of
patients including poor patients [64], patients that already received support before referral to the intervention studied
[66] and non-adherent patients [20]. This precludes conclusions on the effects of these interventions when provided
to all patients. Such patient selection may have led to overestimations in the observed effect of the PE/SE
interventions. On the other hand, selecting patients most in need seems prudent and is in practice applied in
resource-limited settings. Although the number of studies included in the meta-analysis was small, the optimal size
criterion was sufficient both for the overall meta-analysis and stratified analyses as examined by calculation of the
sample size for the overall effect and subgroup analyses [72]. We could not examine for a dose response rate across
all included studies, as most studies did not include a comprehensive description of interventions. However, one
study did show a positive dose-response within their study regarding provision of indirect economic support: among
patients in the intervention group who received the voucher at least once, treatment success rates significantly
improved [47]. Furthermore, the more frequent the vouchers were received by patients, the higher their probability
of treatment success [47]. Plausible heterogeneity was observed and seven out of
PLOS ONE | DOI:10.1371/journal.pone.0154095 April 28, 2016 22 / 27
Effects of Patient Support on Tuberculosis Treatment Outcomes
eleven RCTs had a high risk of bias on one or two domains. However, we did not exclude studies on the basis of
heterogeneity only, as this may introduce bias [42].
Conclusions
This review provides evidence to endorse implementation of SSI in order to improve treatment outcomes. Firstly,
PE and combined PE/SE support have a beneficial impact on treatment suc- cess. Secondly, SE support and a
combination of PE/SE support are associated with reductions in unsuccessful treatment outcomes. No conclusions
can be drawn considering the overall effect of PE and/or SE support on treatment adherence and financial burden
due to a lack of evidence. Our findings need to be interpreted with caution, as the quality of the evidence included in
the meta-analysis is “very low” based on the GRADE approach. In addition, most support included multifaceted
types of interventions, so no conclusions can be drawn on the effect of individual interventions. Simultaneously, this
might signify that multifaceted types of interventions are needed to improve treatment outcomes. High quality
evidence, from well- designed randomized studies in larger sized populations, would provide more certainty on the
effects of different PE and SE interventions. Cluster-randomized studies would provide an opportunity to compare
differential packages and delineate the importance of specific compo- nents. In addition, more systematic data
collection on PE and SE as already used by TB pro- grams to monitor implementation and evaluate its effects and
qualitative data collection in both studies and program settings to assess which interventions are most appreciated
and most feasible to implement on a wide scale, would be useful. Reports should include information on costs and
sustainability to provide information on efficiency and scalability.
Supporting Information
S1 PRISMA Checklist. PRISMA checklist. (DOC)
S1 Fig. The effects of social support on treatment success in non-randomized cohort stud- ies. (PNG)
S2 Fig. The effects of social support on unsuccessful treatment outcomes in non-random- ized cohort studies.
(PNG)
S3 Fig. The effects of social support on unsuccessful treatment outcomes in Case-control studies. (PNG)
S1 Table. Risk of bias assessment–Cochrane collaborations tool for randomized controlled trials. (DOCX)
S2 Table. Risk of bias assessment–New-castle Ottawa scale for non-randomized studies. (DOCX)
S3 Table. Risk of bias assessment–New-castle Ottawa scale for case-control studies. (DOCX)
S1 Web Annex. Full text search strategy per database. (DOCX)
PLOS ONE | DOI:10.1371/journal.pone.0154095 April 28, 2016 23 / 27
Effects of Patient Support on Tuberculosis Treatment Outcomes
Acknowledgments
We thank Nathan Ford and D'Arcy Richardson for review of previous versions of the manuscript.
Author Contributions
Conceived and designed the experiments: SH RH. Performed the experiments: SH RH. Ana- lyzed the data: SH RH.
Wrote the paper: SH RH DC EJ AG.
References
1. WHO (2014) Global tuberculosis report 2014. Geneva: World Health Organization.
2. WHO (reviewed March 2015) Fact sheet N°104. 3. Baral S, Karki D, Newell J (2007) Causes of stigma and discrimination
associated with tuberculosis in
Nepal: a qualitative study. BMC Public Health 7: 211. PMID: 17705841 4. Vijay S, Kumar P, Chauhan LS, Vollepore BH,
Kizhakkethil UP, Rao SG (2010) Risk factors associated with default among new smear positive TB patients treated under DOTS
in India. PLoS One 5: e10043. doi: 10.1371/journal.pone.0010043 PMID: 20386611 5. Eastwood S, Hill P (2004) A
gender-focused qualitative study of barriers to accessing tuberculosis
treatment in the Gambia, West Africa. Int J Tuberc Lung Dis 8: 70–75. PMID: 14974748 6. Torun T, Gungor G, Ozmen I,
Bolukbasi Y, Maden E, Bicakci B, et al. (2005) Side effects associated
with the treatment of multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 9: 1373–1377. PMID: 16468160 7. Richter LM,
Lonnroth K, Desmond C, Jackson R, Jaramillo E, Weil D (2014) Economic Support to
Patients in HIV and TB Grants in Rounds 7 and 10 from the Global Fund to Fight AIDS, Tuberculosis and Malaria. PLoS One 9:
e86225. doi: 10.1371/journal.pone.0086225 PMID: 24489702 8. Tanimura T, Jaramillo E, Weil D, Raviglione M, Lonnroth K
(2014) Financial burden for tuberculosis
patients in low- and middle-income countries: a systematic review. Eur Respir J. 9. Munro SA, Lewin SA, Smith HJ, Engel
ME, Fretheim A, Volmink J (2007) Patient adherence to tubercu-
losis treatment: a systematic review of qualitative research. PLoS Med 4: e238. PMID: 17676945 10.
Ngamvithayapong-Yanai J, Luangjina S, Nedsuwan S, Kantipong P, Wongyai J, Ishikawa N (2013)
Engaging women volunteers of high socioeconomic status in supporting socioeconomically disadvan- taged tuberculosis patients
in Chiang Rai, Thailand. Western Pac Surveill Response J 4: 34–38. doi: 10.5365/WPSAR.2012.3.4.013 PMID: 23908953 11.
Kaona FA, Tuba M, Siziya S, Sikaona L (2004) An assessment of factors contributing to treatment
adherence and knowledge of TB transmission among patients on TB treatment. BMC Public Health 4: 68. PMID: 15625004 12.
WHO (2009) Guidelines for surveillance of drug resistance in tuberculosis– 4th ed. WHO/HTM/TB/
2009.422. Jenewa: Organisasi Kesehatan Dunia. 13. Zignol M, Hosseini MS, Wright A, Weezenbeek CLv, Nunn P, Watt
CJ, et al. (2006) Global Incidence of
Multidrug-Resistant Tuberculosis. Journal of Infectious Diseases 194: 479–485. PMID: 16845631
14. MMWR (2003) Treatment of Tuberculosis, American Thoracic Society, CDC, and Infectious Diseases
Society of America. American Journal of Respiratory and Critical Care Medicine 167: 603–662. PMID: 12588714 15.
Pablos-Mendez A, Knirsch CA, Barr RG, Lerner BH, Frieden TR (1997) Nonadherence in tuberculosis
treatment: predictors and consequences in New York City. Am J Med 102: 164–170. PMID: 9217566
16. Frieden TR, Munsiff SS (2005) The DOTS strategy for controlling the global tuberculosis epidemic. Clin
Chest Med 26: 197–205, v. PMID: 15837105 17. M'Imunya JM, Kredo T, Volmink J (2012) Patient education and
counselling for promoting adherence
to treatment for tuberculosis. Cochrane Database Syst Rev 5: Cd006591. doi: 10.1002/14651858. CD006591.pub2 PMID:
22592714 18. WHO (2015) Pursue high-quality DOTS expansion and enhancement. Organisasi Kesehatan Dunia. 19. WHO
(2014) Companion handbook to the WHO guidelines for the programmatic management of drug- resistant tuberculosis. In: Rich
M, Jaramillo E, editors. Geneva, Switzerland: WHO Document Produc- tion Services. 20. Bock NN, Sales RM, Rogers T, DeVoe
B (2001) A spoonful of sugar...: improving adherence to tuber-
culosis treatment using financial incentives. Int J Tuberc Lung Dis 5: 96–98. PMID: 11263524
PLOS ONE | DOI:10.1371/journal.pone.0154095 April 28, 2016 24 / 27
Effects of Patient Support on Tuberculosis Treatment Outcomes
21. Frieden TR (2000) Directly observed treatment, short-course (DOTS): ensuring cure of tuberculosis.
Indian J Pediatr 67: S21–27. PMID: 11129903 22. Volmink J, Matchaba P, Garner P (2000) Directly observed therapy and
treatment adherence. Lancet
355: 1345–1350. PMID: 10776760 23. Jakubowiak WM, Bogorodskaya EM, Borisov SE, Danilova ID, Lomakina OB,
Kourbatova EV (2007)
Social support and incentives programme for patients with tuberculosis: experience from the Russian Federation. Int J Tuberc
Lung Dis 11: 1210–1215. PMID: 17958983 24. Belo MT, Selig L, Luiz RR, Hanson C, Luna AL, Teixeira EG, et al. (2006)
Choosing incentives to stimu-
late tuberculosis treatment compliance in a poor county in Rio de Janeiro state, Brazil. Med Sci Monit 12: Ph1–5. PMID:
16641886 25. Garner P, Smith H, Munro S, Volmink J (2007) Promoting adherence to tuberculosis treatment. Bull
World Health Organ 85: 404–406. PMID: 17639229 26. Wise J (1998) WHO identifies 16 countries struggling to control
tuberculosis. BMJ 316: 955.
27. WHO (Emergency update, 2008) Guidelines for the programmatic management of drug-resistant tuber-
culosis Geneva: World Health Organization.
28. Higgins JPT, Green S (Updated March 2011) Cochrane Handbook for Systematic Reviews of Interven-
tions, Version 5.1.0: The Cochrane Collaboration. 29. Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred
reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 151: 264–269, w264. PMID:
19622511 30. Liu Q, Abba K, Alejandria MM, Sinclair D, Balanag VM, Lansang MA (2014) Reminder systems to
improve patient adherence to tuberculosis clinic appointments for diagnosis and treatment. Cochrane Database Syst Rev 11:
Cd006594. doi: 10.1002/14651858.CD006594.pub3 PMID: 25403701 31. Mattson M, Hall J (2011) Health as Communication
Nexus: A Service-Learning Approach.: Kendall
Hunt Publishing Company. 32. van den Hof S, Collins D, Leimane I, Jaramillo E, Gebhard A (2014) Lessons Learned from
Best Prac-
tices in Psycho-Socio-Economic Support for Tuberculosis Patients. 33. Karumbi J, Garner P (2015) Directly observed
therapy for treating tuberculosis. Cochrane Database
Syst Rev 5: Cd003343. doi: 10.1002/14651858.CD003343.pub4 PMID: 26022367 34. Wells GA, Shea B, O'Connell D, Peterson
J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale
(NOS) for assessing the quality of nonrandomised studies in meta-analyses. 35. Higgins J, Altman D, Sterne J (Updated
September 2008) Chapter 8: Assessing risk of bias in included
studies. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interven- tions. Version 5.0.1: The
Cochrane Collaboration.
36. Higgins J, Deeks J, Altman D (Updated September 2008) Chapter 16: Special topics in statistics. In:
Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions. Version 5.0.1: The Cochrane
Collaboration. 37. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. (2008) GRADE: an
emerging consensus on rating quality of evidence and strength of recommendations. Bmj 336: 924– 926. doi:
10.1136/bmj.39489.470347.AD PMID: 18436948 38. Balshem H, Helfand M, Schünemann HJ, Oxman AD, Kunz R, Brozek J,
et al. (2011) GRADE guide-
lines: 3. Rating the quality of evidence. Journal of clinical epidemiology 64: 401–406. doi: 10.1016/j. jclinepi.2010.07.015
PMID: 21208779 39. Guyatt GH, Oxman AD, Vist G, Kunz R, Brozek J, Alonso-Coello P, et al. (2011) GRADE guidelines: 4.
Rating the quality of evidence—study limitations (risk of bias). Journal of clinical epidemiology 64: 407–415. doi:
10.1016/j.jclinepi.2010.07.017 PMID: 21247734 40. Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P,
et al. (Updated September
2008) Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S (editors), Cochrane Handbook for
Systematic Reviews of Interventions. Version 5.0.1: The Cochrane Collaboration. 41. Higgins JP, Thompson SG, Deeks JJ,
Altman DG (2003) Measuring inconsistency in meta-analyses.
Bmj 327: 557–560. PMID: 12958120
42. Deeks J, Higgins J, Altman D (Updated September 2008) Chapter 9: Analysing data and undertaking
meta-anlysis. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Inter- ventions. Version 5.0.1:
The Cochrane Collaboration. 43. JBIEBNM (2000) Evidence Based Practice Information Sheets for Health Professionals:
Appraising
Systematic Reviews, Changing Practice Sup. 1. The Joanna Briggs Insititute for evidence based nurs- ing and midwifery.
PLoS ONE | DOI:10.1371/journal.pone.0154095 April 28, 2016 25 / 27
Effects of Patient Support on Tuberculosis Treatment Outcomes
44. Jakubowiak WM, Bogorodskaya EM, Borisov SE, Danilova ID, Kourbatova EV (2007) Risk factors
associated with default among new pulmonary TB patients and social support in six Russian regions. Int J Tuberc Lung Dis 11:
46–53. PMID: 17217129 45. Cantalice Filho JP (2009) Food baskets given to tuberculosis patients at a primary health care clinic
in
the city of Duque de Caxias, Brazil: effect on treatment outcomes. J Bras Pneumol 35: 992–997. PMID: 19918632 46. Liefooghe
R, Suetens C, Meulemans H, Moran MB, De Muynck A (1999) A randomised trial of the
impact of counselling on treatment adherence of tuberculosis patients in Sialkot, Pakistan. Int J Tuberc Lung Dis 3: 1073–1080.
PMID: 10599010 47. Lutge E, Lewin S, Volmink J, Friedman I, Lombard C (2013) Economic support to improve tuberculosis
treatment outcomes in South Africa: a pragmatic cluster-randomized controlled trial. Trials 14: 154. doi:
10.1186/1745-6215-14-154 PMID: 23714270 48. Lu H, Yan F, Wang W, Wu L, Ma W, Chen J, et al. (2013) Do transportation
subsidies and living allow-
ances improve tuberculosis control outcomes among internal migrants in urban Shanghai, China? Western Pac Surveill Response
J 4: 19–24. 49. Sudarsanam TD, John J, Kang G, Mahendri V, Gerrior J, Franciosa M, et al. (2011) Pilot randomized
trial of nutritional supplementation in patients with tuberculosis and HIV-tuberculosis coinfection receiv- ing directly observed
short-course chemotherapy for tuberculosis. Trop Med Int Health 16: 699–706. doi: 10.1111/j.1365-3156.2011.02761.x PMID:
21418447 50. Alvarez Gordillo Gdel C, Alvarez Gordillo JF, Dorantes Jimenez JE (2003) [Educational strategy for
improving patient compliance with the tuberculosis treatment regimen in Chiapas, Mexico]. Rev Panam Salud Publica 14:
402–408. PMID: 14769157
51. Thiam S, LeFevre AM, Hane F, Ndiaye A, Ba F, Fielding KL, et al. (2007) Effectiveness of a strategy to
improve adherence to tuberculosis treatment in a resource-poor setting: a cluster randomized con- trolled trial. Jama 297:
380–386. PMID: 17244834 52. Baral SC, Aryal Y, Bhattrai R, King R, Newell JN (2014) The importance of providing
counselling and financial support to patients receiving treatment for multi-drug resistant TB: mixed method qualitative and pilot
intervention studies. BMC Public Health 14: 46. doi: 10.1186/1471-2458-14-46 PMID: 24438351 53. Finlay A, Lancaster J,
Holtz TH, Weyer K, Miranda A, van der Walt M (2012) Patient- and provider-level
risk factors associated with default from tuberculosis treatment, South Africa, 2002: a case-control study. BMC Public Health 12:
56. doi: 10.1186/1471-2458-12-56 PMID: 22264339 54. Garden B, Samarina A, Stavchanskaya I, Alsterlund R, Ovregaard A,
Taganova O, et al. (2013) Food
incentives improve adherence to tuberculosis drug treatment among homeless patients in Russia. Scand J Caring Sci 27:
117–122. doi: 10.1111/j.1471-6712.2012.01009.x PMID: 22671304
55. Janmeja AK, Das SK, Bhargava R, Chavan BS (2005) Psychotherapy improves compliance with tuber-
culosis treatment. Respiration 72: 375–380. PMID: 16088280 56. Davidson H, Schluger NW, Feldman PH, Valentine DP,
Telzak EE, Laufer FN (2000) The effects of
increasing incentives on adherence to tuberculosis directly observed therapy. Int J Tuberc Lung Dis 4: 860–865. PMID:
10985655
57. Farmer P, Robin S, Ramilus SL, Kim JY (1991) Tuberculosis, poverty, and "compliance": lessons from
rural Haiti. Semin Respir Infect 6: 254–260. PMID: 1810004 58. Jahnavi G, Sudha CH (2010) Randomised controlled trial
of food supplements in patients with newly
diagnosed tuberculosis and wasting. Singapore Med J 51: 957–962. PMID: 21221502 59. Macq J, Solis A, Martinez G, Martiny
P (2008) Tackling tuberculosis patients' internalized social stigma
through patient centred care: an intervention study in rural Nicaragua. BMC Public Health 8: 154. doi: 10.1186/1471-2458-8-154
PMID: 18466604
60. Martins N, Morris P, Kelly PM (2009) Food incentives to improve completion of tuberculosis treatment:
randomised controlled trial in Dili, Timor-Leste. Bmj 339: b4248. 61. Morisky DE, Malotte CK, Choi P, Davidson P,
Rigler S, Sugland B, et al. (1990) A patient education pro-
gram to improve adherence rates with antituberculosis drug regimens. Health Educ Q 17: 253–267. PMID: 2228629
62. Sripad A, Castedo J, Danford N, Zaha R, Freile C (2014) Effects of Ecuador's national monetary incen-
tive program on adherence to treatment for drug-resistant tuberculosis. Int J Tuberc Lung Dis 18: 44– 48. doi:
10.5588/ijtld.13.0253 PMID: 24365551 63. Wei X, Zou G, Yin J, Walley J, Yang H, Kliner M, et al. (2012) Providing financial
incentives to rural-to-
urban tuberculosis migrants in Shanghai: an intervention study. Infect Dis Poverty 1: 9. doi: 10.1186/ 2049-9957-1-9 PMID:
23849348
PLOS ONE | DOI:10.1371/journal.pone.0154095 April 28, 2016 26 / 27
Effects of Patient Support on Tuberculosis Treatment Outcomes
64. Zou G, Wei X, Witter S, Yin J, Walley J, Liu S, et al. (2013) Incremental cost-effectiveness of improving
treatment results among migrant tuberculosis patients in Shanghai. Int J Tuberc Lung Dis 17: 1056– 1064. doi:
10.5588/ijtld.12.0799 PMID: 23827030 65. (2015) The World Bank Group. Available: http://data.worldbank.org/country. 66.
Gelmanova IY, Taran DV, Mishustin SP, Golubkov AA, Solovyova AV, Keshavjee S (2011) 'Sputnik': a programmatic approach
to improve tuberculosis treatment adherence and outcome among defaulters. Int J Tuberc Lung Dis 15: 1373–1379. doi:
10.5588/ijtld.10.0531 PMID: 22283898 67. Drabo M, Zerbo R, Berthe A, Ouedrago L, Konfe S, Mugishe E, et al. (2009)
[Community involvement in
tuberculosis care in three rural health districts of Burkina Faso]. Sante Publique 21: 485–497. PMID: 20229641 68. Soares EC,
Vollmer WM, Cavalcante SC, Pacheco AG, Saraceni V, Silva JS, et al. (2013) Tuberculosis
control in a socially vulnerable area: a community intervention beyond DOT in a Brazilian favela. Int J Tuberc Lung Dis 17:
1581–1586. doi: 10.5588/ijtld.13.0152 PMID: 24200272 69. Balshem H, Helfand M, Schunemann HJ, Oxman AD, Kunz R,
Brozek J, et al. (2011) GRADE guide-
lines: 3. Rating the quality of evidence. J Clin Epidemiol 64: 401–406. doi: 10.1016/j.jclinepi.2010.07. 015 PMID: 21208779 70.
Guyatt GH, Oxman AD, Vist G, Kunz R, Brozek J, Alonso-Coello P, et al. (2011) GRADE guidelines: 4.
Rating the quality of evidence—study limitations (risk of bias). J Clin Epidemiol 64: 407–415. doi: 10.
1016/j.jclinepi.2010.07.017 PMID: 21247734 71. Guyatt GH, Oxman AD, Montori V, Vist G, Kunz R, Brozek J, et al. (2011)
GRADE guidelines: 5. Rating the quality of evidence—publication bias. J Clin Epidemiol 64: 1277–1282. doi:
10.1016/j.jclinepi.2011. 01.011 PMID: 21802904 72. Guyatt GH, Oxman AD, Kunz R, Brozek J, Alonso-Coello P, Rind D, et al.
(2011) GRADE guidelines 6.
Rating the quality of evidence—imprecision. J Clin Epidemiol 64: 1283–1293. doi: 10.1016/j.jclinepi. 2011.01.012 PMID:
21839614
73. Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, et al. (2011) GRADE guidelines: 7. Rating the quality
of evidence—inconsistency. J Clin Epidemiol 64: 1294–1302. doi: 10.1016/j.jclinepi. 2011.03.017 PMID: 21803546 74. Guyatt
GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, et al. (2011) GRADE guidelines: 8.
Rating the quality of evidence—indirectness. J Clin Epidemiol 64: 1303–1310. doi: 10.1016/j.jclinepi. 2011.04.014 PMID:
21802903 75. Reeves B, Deeks J, Higgins J, Wells G (Updated September 2008) Chapter 13: Including non-random-
ized studies. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Inter- ventions. Version 5.0.1:
The Cochrane Collaboration. 76. Wingfield T, Boccia D, Tovar M, Gavino A, Zevallos K, Montoya R, et al. (2014) Defining
Catastrophic
Costs and Comparing Their Importance for Adverse Tuberculosis Outcome with Multi-Drug Resistance: A Prospective Cohort
Study, Peru. PLoS Med 11: e1001675. doi: 10.1371/journal.pmed.1001675 PMID: 25025331 77. Lutge EE, Wiysonge CS,
Knight SE, Sinclair D, Volmink J (2015) Incentives and enablers to improve
adherence in tuberculosis. Cochrane Database Syst Rev 9: Cd007952. doi: 10.1002/14651858. CD007952.pub3 PMID: 26333525
78. Sinclair D, Abba K, Grobler L, Sudarsanam TD (2011) Nutritional supplements for people being treated
for active tuberculosis. Cochrane Database Syst Rev: Cd006086. doi: 10.1002/14651858.CD006086. pub3 PMID: 22071828 79.
Toczek A, Cox H, du Cros P, Cooke G, Ford N (2013) Strategies for reducing treatment default in drug-
resistant tuberculosis: systematic review and meta-analysis. Int J Tuberc Lung Dis 17: 299–307. doi: 10.5588/ijtld.12.0537
PMID: 23211716
PLOS ONE | DOI:10.1371/journal.pone.0154095 April 28, 2016 27 / 27
Copyright of PLoS ONE is the property of Public Library of Science and its content may not be
copied or emailed to multiple sites or posted to a listserv without the copyright holder's express
written permission. Namun, pengguna dapat mencetak, download, atau artikel email untuk
penggunaan individu.